Drug Trial Radar · NCT00783692
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Last checked: Nov 20, 2026Latest source record: Jul 21, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,116
Actual
Start
Dec 2008
Primary completion
Mar 2012
Study completion May 2012
Sponsor
- Lead sponsor
- Millennium Pharmaceuticals, Inc.Takeda (TAK)
- Sponsor type
- Industry
- First posted
- Nov 3, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study was to determine the effect of vedolizumab induction treatment on clinical response and remission at 6 weeks and to determine the effect of vedolizumab maintenance treatment on clinical remission at 52 weeks.
Conditions
- Crohn's Disease
Interventions
vedolizumabDrug
Vedolizumab for intravenous infusion
PlaceboOther
Placebo intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Induction Phase: Percentage of Participants Achieving Clinical Remission at Week 6Time frame: Week 6
- Induction Phase: Percentage of Participants With Enhanced Clinical Response at Week 6Time frame: Baseline and Week 6
- Maintenance Phase: Percentage of Participants Achieving Clinical Remission at Week 52Time frame: Week 52
Locations
114 sites in 3 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Apex Clinical Trials
Birmingham, Alabama
Gastrointestinal Bioscience
Los Angeles, California
Paramount Medical Specialty
Montebello, California
Capital Gastroenterology Consultants Medical Group
Sacramento, California
Clinical Applications Laboratories Inc.
San Diego, California
Desta Digestive Disease Medical Center
San Diego, California
University of Colorado Health Sciences Center
Aurora, Colorado
Rocky Mountain Clinical Research, LLC
Golden, Colorado
Gastroenterology of the Rockies
Lafayette, Colorado
Arapahoe Gastroenterology Associates P.C.
Littleton, Colorado
South Denver Gastroenterology
Lone Tree, Colorado
Lynn Institute of Pueblo
Pueblo, Colorado
Connecticut Gastroenterology Institute
Bristol, Connecticut
Gastroenterology Center of Connecticut, P.C.
Hamden, Connecticut
University of Florida
Gainesville, Florida
University of Florida, Jacksonville
Jacksonville, Florida
East Coast Institute for Research
Jacksonville, Florida
Borland-Groover Clinic
Jacksonville, Florida
Center for Advanced Gastroenterology
Maitland, Florida
Osler Clinical Research
Melbourne, Florida
University of Miami Miller School of Medicine
Miami, Florida
United Medical Research Institute
New Smyrna Beach, Florida
Compass Research LLC
Orlando, Florida
Internal Medicine Specialists
Orlando, Florida
University of South Florida
Tampa, Florida
West Wind'r Research & Development, LLC
Tampa, Florida
Shafran Gastroenterology Center
Winter Park, Florida
Atlanta Gastroenterology Associates
Atlanta, Georgia
Southeast Regional Research Group
Columbus, Georgia
Atlanta Center for Gastroenterology, P.C.
Decatur, Georgia
Gastroenterology Associates of Central Georgia
Macon, Georgia
Digestive Research Associates
Newnan, Georgia
St. Joseph's/Candler Health System
Savannah, Georgia
DLW Research System
Snellville, Georgia
Rush University Medical Center
Chicago, Illinois
University of Chicago Medical Center
Chicago, Illinois
Carle Clinic Association P.C.
Urbana, Illinois
Indianapolis Gastroenterology & Hepatology, Inc.- ARC
Indianapolis, Indiana
Digestive & Liver Consultants
Clive, Iowa
Showing 40 of 114 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.